Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Inclusion Criteria:

1. Sign the Informed consent form(ICF) and be able to follow the requirements of studyprotocol;

2. Age ≥18 years;

3. Eastern Cooperative Oncology Group (ECOG) performance status between 0 and 2;

4. Histopathologically confirmed diagnosis of DLBCL;

5. The investigator judges that the patient's current condition requires furthertreatment;

6. Patients should have at least one bi-dimensionally measurable lesion;

7. Expected survival is more than 12 weeks;

Exclusion Criteria:

1. Patients with known primary or secondary central nervous system lymphoma (CNSL) orthe presence of clinical symptoms suggestive of CNSL;

2. Women who are pregnant (positive pregnancy test during the screening period) orbreastfeeding;

3. Organ insufficiency;

4. Currently known history of liver disease, including cirrhosis, alcoholic liver,known active infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV):

5. History of significant organ bleeding, including gastrointestinal bleeding,hematencephalon, haemoptysis, etc., within 8 weeks prior to the first dose of studydrug;

6. Known risk of bleeding, such as coagulation factor deficiency, vascular hemophilia;or the patient is receiving vitamin K antagonist (warfarin);

7. Toxicities from prior anticancer therapy not resolved to Grade ≤ 1 (except foralopecia and decreased appetite);

8. Clinically significant active infection;